GRI Bio, Inc.(GRI)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.1M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
GRI Stock Analysis & AI Quality Score
AI stock analysis and institutional research for GRI Bio, Inc. (GRI), a Healthcare sector company. GRI is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.1m in revenue. Based on the latest XBRL financial filings (Q1 2026), GRI Bio, Inc. reports net income of $-2.0M, free cash flow of $-3.7M. Top institutional holders of GRI by reported 13-F value include GEODE CAPITAL MANAGEMENT,, UBS Group AG, Tower Research Capital (TRC), based on the most recent SEC filings. GRI trades on the Nasdaq exchange and files with the SEC under CIK 1824293. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GRI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GRI Bio, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-2.0M
Free Cash Flow
Q1 2026
$-3.7M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-45.7% YoYOperating Income
-45.4% YoYEPS (Diluted)
+92.1% YoYTotal Assets
+51.0% YoYOp. Cash Flow
-18.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Net Income | $-12.0M -45.7% | $-8.2M +37.0% | $-13.0M -305.3% | $-3.2M |
| Operating Income | $-12.0M -45.4% | $-8.2M +27.7% | $-11.4M -408.6% | $-2.2M |
| EPS (Diluted) | $-121.80 +92.1% | $-1545.55 +69.2% | $-5018.09 -20012.6% | $-24.95 |
| Total Assets | $8.7M +51.0% | $5.7M +94.1% | $3.0M +671.8% | $383.0K |
| Operating Cash Flow | $-10.2M -18.3% | $-8.6M +4.2% | $-9.0M -728.6% | $-1.1M |
AI Insight: GRI Financial Trends
GRI Bio remains pre-revenue with persistent quarterly losses of $2–3M, while equity has volatile swings and operating cash outflows worsening.
• Net and operating losses steady at $2–3M per quarter across 8-quarter span; no revenue reported.
• Operating cash flow deteriorated to $4M outflow in Q1 2026, worst in dataset.
• Equity eroded from $5M (Q2 2024) to $11M (Q1 2026), driven by cumulative losses and capital raises.
⚠ Equity spiked to $11M in Q1 2026 after falling to $1M in Q1 2025 — suggests emergency capital injection.
⚠ Burn rate accelerated Q1 2026 cash outflow to $4M with no offsetting revenue; runway clarity critical.
AI Insight: GRI Ratio Trends
GRI Bio's profitability metrics show sharp improvement in Q1 2026, with ROE rebounding to -75.8% from -177.0% in Q4 2025.
• ROE improved 101.2 percentage points from Q4 2025 (-177.0%) to Q1 2026 (-75.8%), signaling reduced operating losses.
• ROA and ROIC both near -70% to -76% in Q1 2026, reflecting persistent unprofitability but narrower negative margins than prior quarters.
⚠ Company remains unprofitable across all return metrics; TTM ROE at -103.4% and ROA at -96.2% underscore sustained cash burn.
⚠ Debt-to-equity ratio absent; leverage position and balance-sheet health cannot be assessed from available data.
Get alerted when GRI's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for GRI Bio, Inc. including:
Top Institutional Holders of GRI
GEODE CAPITAL MANAGEMENT, LLC
$42.2K18,438 shUBS Group AG
$20.0K8,722 shTower Research Capital LLC (TRC)
$2.4K1,060 shBlackRock, Inc.
$16.007 shSBI Securities Co., Ltd.
$9.004 shDANSKE BANK A/S
$5.002 sh
| Fund | Value | Shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | $42.2K | 18,438 |
| UBS Group AG | $20.0K | 8,722 |
| Tower Research Capital LLC (TRC) | $2.4K | 1,060 |
| BlackRock, Inc. | $16.00 | 7 |
| SBI Securities Co., Ltd. | $9.00 | 4 |
| DANSKE BANK A/S | $5.00 | 2 |
More Healthcare Companies
View all Healthcare →Put GRI on your watchlist
Track score changes the day GRI Bio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is GRI a good stock to buy?
13F Pro's AI-powered analysis of GRI Bio, Inc. (GRI) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GRI are available on the GRI stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own GRI?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GRI. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GRI Bio, Inc.'s investment landscape.